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Integrate CRISPR/Cas9 for protein 
expression of HLA-B*38:68Q via 
precise gene editing
Yuxin Yin, Elaine F. Reed & Qiuheng Zhang  
The determination of null- or low-expressed HLA alleles is clinically relevant in both hematopoietic stem 
cell transplantation and solid organ transplantation. We studied the expression level of a questionable 
(Q) HLA-B*38:68Q allele, which carries a 9-nucleotide (nt) deletion at codon 230–232 in exon 4 of 
HLA-B*38:01:01:01 using CRISPR/Cas9 gene editing technology. CRISPR/Cas9 gene editing of HLA-
B*38:01:01:01 homozygous EBV B cell line resulted in one HLA-B*38:68Q/B*38:01:01:01 heterozygous 
and one HLA-B*38:68Q homozygous clone. Flow cytometric analysis of monoclonal anti-Bw4 antibody 
showed the protein expression of HLA-B*38:01:01:01 in homozygous cells was 2.2 fold higher than 
HLA-B*38:68Q/B*38:01:01:01 heterozygous cells, and the expression of HLA-B*38:68Q/B*38:01:01:01 
heterozygous cells was over 2.0 fold higher than HLA-B*38:68Q homozygous cells. The HLA-B*38:68Q 
expression was further confirmed using anti-B38 polyclonal antibody. Similarly, the expression of the 
HLA-B*38:01:01:01 homozygous cells was 1.5 fold higher than that of HLA-B*38:68Q/B*38:01:01:01 
heterozygous cells, and the HLA-B*38:68Q/B*38:01:01:01 heterozygous cells was over 1.6 fold higher 
than that of HLA-B*38:68Q homozygous cells. The treatment of HLA-B*38:68Q homozygous cells with 
IFN-γ significantly increased its expression. In conclusion, we demonstrate that HLA-B*38:68Q is a 
low-expressing HLA allele. The CRISPR/Cas9 technology is a useful tool to induce precise gene editing in 
HLA genes to enable the characterization of HLA gene variants on expression and function.
Immune recognition of infectious pathogens is mediated through the presentation of foreign peptides by the 
Human Leukocyte Antigen (HLA) molecules1. The HLA class I (HLA-A, -B and -C) and class II (HLA-DR, -DQ 
and -DP) are the most polymorphic genes in the human genome with 18,771 different HLA alleles identified 
(IMGT/HLA v3.33.0)2. The high level of HLA polymorphism reflects its biological importance to present a large 
diversity of peptides to the immune system and trigger effective immune responses3. In allogeneic hematopoietic 
stem cell transplantation (HSCT), HLA mismatches between donor and recipient leads to strong alloimmune 
responses that result in either graft versus host disease (GVHD) or engraftment failure4–6.
Mutations such as insertions, deletions in HLA sequences can lead to the introduction of stop codons and/
or incorrectly spliced products that result in aberrant expressed alleles. HLA null alleles (N) are characterized by 
the lack of antigen expression of the HLA molecule on cell surface2. Failure to identify HLA null alleles in donors 
may result in HLA mismatches that can stimulate allogeneic T cells and trigger GVHD in HSCT7. A ‘Q’ suffix is 
used for HLA alleles that their expressions have not been confirmed and remain ‘Questionable’. In HSCT, if the 
presence of a questionable allele in the donor is in fact a null allele, mistyping the null allele results in an antigen 
mismatch between the donor and the recipient and increases the risk of GVHD7. On the contrary, mistyping of 
a lowly expressed HLA allele as a null allele in the recipient can lead to inaccurate donor selection and result in 
GVHD as well. Therefore, questionable alleles require confirmation of their actual HLA expression level. For 
example, HLA-A*23:19Q has a single polymorphism at position 619 (G > A) compared to HLA-A*23:01:01. 
Gerritsen et al. demonstrated that HLA-A*23:19Q has no expression by serology and flow cytometry, there-
fore it should be reclassified as a null allele8. Hirv et al.9 reported a patient, who carried HLA-A*30:14L and 
HLA-A*02:01 alleles, was mistyped as HLA-A*02:01 homozygous. The mistyping of HLA-A*30:14L led to severe 
GVHD in the patient transplanted with HSCT from an HLA-A*02:01 homozygous donor. Currently, there are 
663 null alleles (N), 44 questionable alleles (Q), 5 low expression alleles (L), and 1 soluble alleles (S) identi-
fied in IMGT/HLA data base2. The HLA matching of the questionable alleles between the donor and recipient 
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remains challenging. Therefore, it is important to determine the expression patterns of abnormally expressed 
HLA variants7.
The CRISPR (clustered regularly interspaced short palindromic repeats) is an adoptive immune system in bac-
teria that protects the bacterium from invading foreign genetic elements such as plasmid and bacteriophages10. 
The CRISPR/Cas9 system contains two components: a guide RNA (gRNA) and a CRISPR-associated endonucle-
ase (Cas protein)11,12. The gRNA is a short RNA composed of a scaffold sequence needed for Cas-binding and a 
user-defined ∼20 nucleotide spacer that defines the genomic target to be modified13. The gRNA spacer sequence 
could be designed to target DNA sites with Protospacer Adjacent Motif (PAM)14,15. The most common PAM 
sequence recognized by Cas9 is NGG that is found directly downstream of the target DNA. The CRISPR/Cas9 
cuts double strand DNA to generate double strand breaks (DSBs) between 3–4 bp upstream of the NGG PAM 
under the guidance of gRNA16. The DSBs can be repaired by non-homologous end joining (NHEJ), which is an 
error-prone process that introduces unpredictable insertions and deletions (indels); DSBs can also be repaired by 
homology directed repair (HDR) with the presence of DNA template, which induces desired DNA editing11,12,17. 
Two types of the DNA template can be used for HDR: a small single stranded DNA (ssDNA) oligonucleotide with 
30–67 nt homology arms flanking the gene editing site18 or a double stranded DNA (dsDNA) plasmid with long 
homology arms of 1–3 kb19.
The recent discovery of CRIPSR/Cas9 system provides a faster and more economical approach to gene edit-
ing20 compared to the traditional zinc-finger nucleases (ZFNs)21 and transcription activator-like effector nuclease 
(TALEN) methods22. The goal of this study was to generate homozygous and heterozygous cells carrying the 
HLA-B*38:68Q with deletion at codon 230–232 at exon 4 using CRISPR/Cas9 gene editing to study the effect of 
this mutation on HLA-B*38:01:01:01 expression.
Results
crRNA design and selection. We identified a new HLA B allele that is similar to HLA-B*38:01:01:01 
except for a nine-nucleotide deletion (5′-CTTGTGGAG-3′) at codon 230 to 232 that results in a coding shift 
at α3 domain of HLA-B38 (Fig. 1A). The sequence was submitted to the GenBank database (accession number 
MF069211) and IMGT/HLA databases (submission number HWS10028807). Since the expression level of this 
novel B*38 allele is unknown, it was named HLA-B*38:68Q. To determine if the deletion at codon 230–232 
affected the level of protein expression, the homozygous HLA-B*38:01:01:01 EBV B cell line TEM665 was used 
to generate homozygous HLA-B*38:68Q alleles to study its expression (Fig. 1B). GeneArtTM CRISPR Search and 
Design Tool was used to design crRNAs targeting the DNA sequences close to the 9-nt deletion site at exon 4 of 
Figure 1. crRNA and ssDNA target design. (A) Comparison of HLA-B*38:01:01:01 and HLA-B*38:68Q 
in nucleotide and protein sequences. Yellow box highlights the 9-nt deletion mutation and “.” indicates the 
deletion. Numbers above sequence correspond to amino acid codon positions. (B) HLA typing of TEM665 
homozygous HLA-B*38:01:01:01 EBV transformed B cell line used for gene editing. (C) Design of crRNA and 
ssDNA target on HLA-B*38:01:01:01. crRNA1 and crRNA2 are colored in green. The Protospacer Adjacent 
Motif (PAM) recognition sites are marked in blue. The red box indicates the location of 9-nt deletion. “.” means 
that the ssDNA oligo contains the 9-nt deletion. Blue arrows show the position of double strand breaks (DSBs) 
that should be introduced by CRISPR/Cas9.
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HLA-B*38:01:01:01 (Fig. 1C). crRNA1 (5′-GGATGGCGAGGACCAAACTC-3′) was designed to recognize −12 
to −31 bp upstream of the 9-nt deletion, and crRNA2 (5′-TGGTCTGGTCTCCACAAGCT-3′) was designed to 
recognize −2 to +9 bp sequence of the 9-nt deletion. Both crRNAs share a ssDNA target with a 67-nt of left arm 
and a 30-nt of right arm of the deletion site (Fig. 1C). The crRNA1 and crRNA2 were then mixed with universal 
tracrRNA to form gRNA1 and gRNA2. Next, Cas9 protein (1.5 µg) and gRNA1/gRNA2 (360 ng) were mixed 
to form Cas9 ribonucleoprotein (RNP), respectively18. Twenty four electroporation conditions were tested to 
optimize transportation efficiency using Neon transfection system23 (Supplemental Table 1). The program of the 
highest transportation efficiency (58.4%) was selected for transfecting HLA-B*38:01:01:01 homozygous EBV B 
cell line. Our results showed that gRNA1 induced 22.6% DSB cleavage and gRNA2 induced 13.8% DSB cleavage 
using GeneArt® Genomic Cleavage Detection assay. The gRNA1 was chosen for transfection with ssDNA target 
due to its high efficiency.
Generation of HLA-B*38:68Q clones using CRISPR/Cas9 gene editing. Gene editing of 
HLA-B*38:01:01:01 homozygous EBV B cell line by CRISPR/Cas9 using gRNA1 resulted in 25 single cell derived 
clones. The 25 clones were then sequenced by Next Generation Sequencing (NGS) to ensure correct gene edit-
ing was achieved (Fig. 2). The CRISPR/Cas9 editing is usually bi-allelic. Our results showed a total of 41 alleles 
were edited while 9 alleles had no editing. These 41 edited alleles resulted in 21 (84%) modified clones with 7 
genotypes (Fig. 2). Of the 25 clones, 5 alleles (10%) were edited through the HDR pathway and 36 alleles (72%) 
were edited through the NHEJ pathway. The most frequent editing was an A deletion at codon 225 through 
NHEJ pathway which resulted in 11 (44%) clones with homozygous A deletion (Clone 7, Fig. 2). The CRISPR/
Cas9 editing generated 5 HLA-B*38:68Q alleles that resulted in one HLA-B*38:68Q homozygous clone and one 
HLA-B*38:01:01:01/B*38:68Q heterozygous clone. The sequencing of the entire HLA-B gene from the 5′ UTR 
to 3′ UTR of the HLA-B*38:68Q homozygous clone and a HLA-B*38:01:01:01/B*38:68Q heterozygous clone 
showed that other than the correct 9-nt deletion on codon 230–232 at exon 4, there was no non-specific gene 
editing detected in the rest of the HLA-B*38:68Q alleles in both clones (Fig. 3).
HLA-B*38:68Q shows inferior cell surface expression by flow cytometry. Both HLA-B*38:68Q 
and HLA-B*38:01:01:01 express Bw4 epitope in α1-helix at position 77–8324, therefore anti-Bw4 antibody was 
used to detect the expression levels of HLA-B*38:68Q homozygous and HLA-B*38:68Q/B*38:01:01:01 heterozy-
gous clones. The monoclonal anti-Bw4 antibody does not cross reactive to A66, C12 HLA antigens expressed on 
the HLA-B*38:01:01:01 homozygous TEM665 EBV B cell line using Luminex Single Antigen Bead (SAB) testing 
(Supplemental Fig. 1). The K562 cell line lacking HLA molecule expression and the Bw6 homozygous AOH749 
EBV B cell line were used as negative controls. The wild type HLA-B*38:01:01:01 homozygous TEM665 EBV 
B cell line was used as a positive control (Fig. 1B). Flow cytometry analysis showed the median fluorescence 
intensity (MFI) of antibody binding to HLA-B*38:01:01:01 was at 58,080 ± 5,368 MFI in the HLA-B*38:01:01:01 
homozygous TEM665 EBV B cell line compared to 10,383 ± 639 MFI in homozygous HLA-B*38:68Q cells using 
2 μL of anti-Bw4 antibody (Fig. 4). As expected, HLA expression was negative in AOH749 and K562 cell line 
(Fig. 4). These results indicate that HLA-B*38:68Q is expressed on the cell surface, yet at a significantly lower 
level than the wild type HLA-B*38:01:01:01 molecule. Notably, the expression of HLA-B*38:01:01:01 homozy-
gous cell line was 2.2 fold higher than HLA-B*38:68Q/B*38:01:01:01 heterozygous clones (24,067 ± 2,066 MFI, 
P < 0.01). In addition, the expression of HLA-B*38:68Q/B*38:01:01:01 heterozygous cells was 2.0 fold higher 
than HLA-B*38:68Q homozygous clone (P < 0.001), suggesting HLA-B*38:68Q exhibits a reduction of antigen 
expression in a gene dose dependent manner (Fig. 4). Similar results were found using 0.5 μL and 1 μL of anti-Bw4 
antibody (Fig. 4).
Figure 2. Single cell clones derived by CRISPR/Cas9-mediated gene editing. Nucleotides highlighted in red are 
the position with the 9-nt deletion. The Protospacer Adjacent Motif (PAM) sequence is highlighted in green. “.” 
indicates the deletion. The frequency of each single cell derived clone as well as the relative percentage of wild 
type (WT), NHEJ, and HDR were listed (n = 25).
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Figure 3. Confirmation of HLA-B*38:68Q gene editing by NGS sequencing. (A) HLA-B*38:01:01:01 
homozygous; (B) HLA-B*38:68Q/B*38:01:01:01 heterozygous; (C) HLA-B*38:68Q homozygous. The 
histograms display NGS read coverage from 5′ UTR to 3′ UTR. The purple color represents exons. The height 
of the blue (specific reads from one allele), green (homozygous sequences), and grey (sequences shared by 
both alleles) colors indicates relative read depth. The highest and lowest coverages are shown with numbers. 
Sequence in red indicates the location of 9-nt, and “.” indicates the 9-nt deletion.
Figure 4. Flow cytometric analysis of HLA-B38 protein expression using monoclonal antibody. (A) HLA-B 
expression detected in HLA-B*38:01:01:01 homozygous (blue), HLA-B*38:68Q/B*38:01:01:01 heterozygous 
(red), HLA-B*38:68Q homozygous (green), and negative controls (AOH749 purple and K562 in orange) using 
anti-Bw4 IgG antibody. Samples were tested in triplicate and the expression level is shown as mean fluorescence 
intensity (MFI) ± SD. (B) Representative histograms of HLA-B expression in HLA-B*38:01:01:01 homozygous, 
HLA-B*38:68Q/B*38:01:01:01 heterozygous, HLA-B*38:68Q homozygous and negative controls using 0.5 μL 
of anti-Bw4 IgG antibody. Normalized to mode scales all channels as a percentage of the maximum count. 
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, and NS indicates the variables are not significant.
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The expression of the HLA-B*38:68Q was further confirmed using human polyclonal antibody against HLA-B38 
at neat and at 1:2 dilution. HLA-B38 antibody recognizes epitopes at 80I and 158 T of the α1 and α2 helixes of HLA 
class I molecule25. The polyclonal anti-B38 antibody does not cross react to A66, C12, DR14, DR52, DQ5 and DP1 
HLA antigens expressed on the HLA-B*38:01:01:01 homozygous TEM665 EBV B cell line using Luminex SAB test 
(Supplemental Fig. 2). Luminex SAB testing showed the MFI of the HLA-B38 antibody was 22,636 at neat and 14,551 at 
1:2 dilution. Our results showed the expression of HLA-B38 in the HLA-B*38:01:01:01 homozygous cells (27,730 ± 784 
MFI) was 1.5 fold higher than that of HLA-B*38:68Q/B*38:01:01:01 heterozygous cells (18,184 ± 387 MFI, P < 0.0001), 
and the HLA-B*38:68Q/B*38:01:01:01 heterozygous cells was over 1.6 fold higher than HLA-B*38:68Q homozygous 
cells at neat (11,427 ± 190 MFI, P < 0.0001, Fig. 5). Similar results were found using anti-B38 antibody at 1:2 dilution. In 
summary, this data demonstrates that HLA-B*38:68Q is a low-expressed HLA allele, not a null allele.
Allograft rejection often correlates with increased cytokine production including IFN-γ26. We therefore tested 
if the expression of HLA-B*38:68Q will be stimulated by IFN-γ under inflammatory environment. Our results 
showed that in the HLA-B*38:68Q homozygous cells, the treatment of IFN-γ significantly increased the HLA-B 
expression and resulted in a binding of 36,036 ± 887 MFI, 1.9 fold higher than the HLA-B*38:68Q homozy-
gous cells without IFN-γ treatment (19,379 ± 900 MFI, P < 0.0001, Fig. 6). Similarly, in the HLA-B*38:01:01:01 
homozygous cells, the expression of HLA-B treated with IFN-γ was at 57,646 ± 357 MFI, which was 1.2 fold 
higher than the untreated group (46,642 ± 231 MFI, P < 0.0001). The results showed that although the expression 
of HLA-B*38:68Q can be upregulated by IFN-γ treatment, the upregulation of HLA-B expression was much lower 
compared to IFN-γ treated HLA-B*38:01:01:01 homozygous cells (Fig. 6).
Discussion
In this study, we reported efficient HLA-B*38:01:01:01 gene modification and expression in an EBV B cell line using the 
CRISPR/Cas9 system. We successfully introduced gene editing in 84% of clones and achieved precise deletion at codon 
230–232 at exon 4 in 5 alleles. Similar to other publications, the CRISPR/Cas9 gene editing of HLA-B*38:01:01:01 
involved DNA repair via either NHEJ or HDR pathway27. However, even in the presence of guided DNA templates, 
72% of gene editing was through the NHEJ repair pathway compared to 10% in HDR pathway. HDR pathway provides 
desired repair of the target DNA in the presence of template DNA. The low incidence of HDR makes the selection of 
precise gene editing challenging. In order to achieve higher HDR gene editing efficiency, the DSBs induced by CRISPR/
Cas9 nuclease should be in close proximity to the edit site18. The homologous recombination rate could be increased 
with larger flanking sequences, therefore standard gene deletion/disruption protocols typically use flanking regions 
over 1 kb on either side of the target gene to increase HDR28. The evidence of using cell lines deficient in NHEJ pathways 
increased the levels of HDR suggesting these two pathways are competitive29. Recent studies have demonstrated the use 
of KU70, KU80 or DNA ligase IV to suppress key NHEJ molecule can increase HDR pathway30.
Our study successfully demonstrated that the deletion at codon 230–232 at exon 4 in HLA-B*38:01:01:01 
reduced HLA-B38 antigen expression on the cell surface using CIRSPR/Cas9 system. The expression of the 
HLA-B*38:01:01:01 homozygous allele was 2.2 fold higher than HLA-B*38:68Q/B*38:01:01:01 heterozygous cells. 
Further, HLA-B*38:68Q/B*38:01:01:01 protein expression in heterozygous cells was >2.0 fold higher compared 
to HLA-B*38:68Q homozygous cells. Similar results were found using the anti-B38 polyclonal antibody. These 
Figure 5. Flow cytometric analysis of HLA-B38 expression using polyclonal antibody. HLA-B38 expression is 
shown in HLA-B*38:01:01:01 homozygous (blue), HLA-B*38:68Q/B*38:01:01:01 heterozygous (red), HLA-
B*38:68Q homozygous (green) and K562 negative control (purple) using anti-B38 antibody from UCLA serum 
exchange. Samples were tested in triplicate and the expression level is shown as mean fluorescence intensity 
(MFI) ± SD. ***P < 0.001, ****P < 0.0001, and NS indicates the variables are not significant.
6Scientific RepoRts |          (2019) 9:8067  | https://doi.org/10.1038/s41598-019-44336-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
results suggested that the deletion of three amino acids (LVE) at exon 4 of HLA-B*38:01:01:01 reduces the protein 
expression level. In addition, our data also showed that after IFN-γ treatment, the expression of HLA-B*38:68Q 
was significantly increased compared to the untreated cells. These results suggested that HLA-B*38:68Q may 
still play an important role in allograft rejection31. However, the expression increase of the HLA-B*38:68Q with 
the IFN-γ treatment was much lower compared to the HLA-B*38:01:01:01 homozygous cells. The cause of the 
reduced expression of HLA-B*38:68Q allele is unclear and requires additional study. However, possible mecha-
nisms that proposed for lower HLA expression including aberrant dominate splice site, such as A*24:02:03Q32 
and HLA conformation alterations caused by disulfide bond changes, such as A*32:11Q33.
Currently, there are 44 questionable HLA alleles (Q) in IMGT/HLA data base2. The frequency of these questiona-
ble alleles has not been well established, particularly the HLA allele frequency is largely based on the Caucasian pop-
ulation. Therefore, the frequency of these questionable alleles may be underestimated in other populations. With the 
advancement of the full gene HLA sequencing by NGS technology, the laboratory is able to obtain high resolution 
HLA typing with minimum ambiguities. However, due to additional sequencing information on exons outside the 
antigen recognition sites (ARS) and introns, it is likely that more questionable alleles will be discovered. The knowl-
edge of the expression level of these questionable alleles may be important for donor selection in HSCT. Petersdorf 
et al. demonstrated that increasing expression level of the patient’s mismatched HLA-C allele was associated with 
increased risk of grades III-IV acute GVHD with odds ratio of 1.34 in HSCT34. In addition, the understanding of the 
expression level can also help to identify donors with the least immunogenic mismatches, or select donors to cross 
permissive immunological barriers for highly sensitized patients in solid organ transplantation. These questionable 
alleles could also be potential null alleles. Failure to identify HLA null alleles in donors may cause severe GVHD in 
HSCT7. Increasing knowledge of the expression level of HLA variant alleles will help to improve the understanding 
of HLA allogenicity in both HSCT and solid organ transplantation. The CRISPR/Cas9 system provides an effective 
tool to study the expression level of these variant HLA alleles. In addition, CRISPR/Cas9 can also introduce inser-
tions and deletions at the UTRs, exons and introns to study the regulations and functions of HLA genes.
CRISPR/Cas9 has been used to facilitate correction of mutated genes in various diseases. Recently, CRISPR/
Cas9 has been used to treat single nucleotide polymorphism in the β-globulin gene to treat sickle cell diseases 
in a mouse model35. The chimeric antigen receptor (CAR) modified T cells have been applied to various can-
cers, especially in B cell hematologic malignancies36. With the application CRISPR/Cas9 system, Liu et al.37 have 
successfully down regulated the expression of HLA class I and TCRα to generate a universal chimeric antigen 
receptor (CAR) T cells. The CRISPR/Cas9 technology has also come under the spotlight in transplantation. Entry 
of human immunodeficiency virus (HIV) into target cells requires both CD4 and CCR5 receptors38. A 32-base 
pair deletion in CCR5 (CCR5-Δ32) is associated with reduced HIV transmission risk and delayed disease pro-
gression39. In HIV+ patients with hematological malignancies, gene editing using CRISPR/Cas940 has been used 
to generate homozygous CCR5-Δ32 deletion in CD34+ cells to introduce HIV resistance. Currently, there are 
several ongoing clinical trials evaluating the safety of transplantation of CRISPR modified CCR5-Δ32 CD34+ 
cells in HIV+ patients with hematological malignances41,42. In conclusion, the CRISPR/Cas9 system is a powerful 
gene editing tool that can be used to study HLA gene expression and function and improve HLA matching in 
hematopoietic stem cell and solid organ transplantation. Modification of HLA gene expression by CRISPR/Cas9 
also promises to provide new approaches for cellular therapies in transplantation.
Figure 6. IFN-γ induced HLA-B38 cell surface expression. HLA-B expression of HLA-B*38:01:01:01 
homozygous cell line (untreated in purple and IFN-γ treated in orange) and HLA-B*38:68Q homozygous cell 
line (untreated in blue and IFN-γ treated in red) was determined using anti-Bw4 IgG antibody. Samples were 
tested in triplicate and the expression level is shown as mean fluorescence intensity (MFI) ± SD. ****P < 0.0001, 
and NS indicates the variables are not significant.
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Material and Methods
HLA-B*38:68Q was submitted to the GenBank database (accession number MF069211) and IMGT/HLA data-
base (submission number HWS10028807) with full genomic allele sequence as a questionable allele due to its 
unknown surface expression by our center in 201743. Research approval for performing CRISPR/CAS9 on the 
sample was granted by the UCLA Institutional Review Board (IRB#14–000516).
Cell lines. An HLA-B*38:01:01:01 homozygous EBV transformed B cell line TEM665 (from International 
Histocompatibility Workshop, IHW9057, Fig. 1B) was selected for gene editing, and in addition, a Bw6 homozygous 
EBV B cell line AOH749 (from AOH Workshop, AOH9004) and/or K562 (from UCLA Immunogenetics Center) which 
lacks HLA expression were used as negative controls for monoclonal or polyclonal antibody test. AOH749 expresses 
HLA A31, B65, Bw6, C8, DR1, DQ5, DP3 and DP0401, which does not cross reactive to the anti-Bw4 antibody. All 
cell lines were cultured in RPMI-1640 (GE Healthcare Life Sciences, USA) containing 20% FBS (Omega, USA), 1% 
Amphotericin B (Corning, USA), 1% Penicillin Streptomycin Solution (Corning, USA), 1% Gibco™ Sodium Pyruvate 
(100 mM) (ThermoFisher, USA), 1% Gibco™ MEM Non-Essential Amino Acids Solution (ThermoFisher, USA), and 
0.1% Gibco™ 2-Mercaptoethanol (55 mM) (ThermoFisher, USA). All cultures were maintained in 5% CO2, 37 °C.
crRNA design and Cas9 Ribonucleoproteins (RNPs) complex formation. Oligonucleotides of 
crRNA sequences were designed with the GeneArtTM CRISPR Search and Design Tool. crRNAs (Synthesized by 
ThermoFisher, USA) and tracrRNA from TrueGuide™ Synthetic gRNA kit (ThermoFisher, USA) were re-suspended 
using DNA Suspension Buffer pH 8.0 (Teknova, USA) to make a concentration of 100 pM. In Brief, the reaction of 
forming gRNA consisted of 10 μL crRNA, 10 μL tracrRNA, 10 μL annealing buffer, and 20 μL nuclease-fee H2O, 
making a final volume of 50 μL. Then the mixture was incubated at 95 °C for 5 mins followed by 10 mins on 78 °C, 
and then 25 °C for 5 mins. To make Cas9 RNPs, mixing the following items: 11.25 μL gRNA formed in previous step, 
7.5 μL Cas9 Nuclease V2 (5 μg/μL) (ThermoFisher, USA), and 131.25 μL buffer R from Neon kit (Invitrogen, USA), 
making a final volume of 150 μL. The mixture was incubated at room temperature for 10~20 mins.
ssDNA target design/Homologous recombination assays. To create homologous recombination (HR) 
assays, two gRNAs target the sequence near the deletion site within the HLA-B gene were designed and synthe-
sized18. The Cas9 RNPs were then used to transfect cells via Neon® electroporation (Invitrogen, USA) for 24-well 
format electroporation transfection testing for B cell line. The genomic cleavage efficiency was then evaluated using 
the GeneArt® Genomic Cleavage Detection kit (ThermoFisher, USA) at 48 h post transfection. The cleavage effi-
ciencies were calculated based on the relative agarose gel band intensity, which was quantified using a high sensitiv-
ity DNA chip on TapeStation 2200 (Agilent, USA). Cleaved efficiency was calculated following the manufacturer’s 
instruction. A program with voltage set at 1700 V, pulse width set at 20 ms, and one pulse was used for the subse-
quent study. The gRNA with highest editing was selected for the subsequent HR assays. For ssDNA target design, 
typically the mutation site was positioned at the center flanked by 67-nt to 30-nt on each side (Fig. 1C). To measure 
homologous recombination efficiency, the ssDNA target was co-transfected with Cas9 RNPs into cells via electro-
poration. The genomic loci were PCR-amplified using the corresponding primers and then subjected to GeneArt® 
Genomic Cleavage Detection assay (ThermoFisher, USA) for restriction enzyme digestion.
Culture of single cell derived clones. Transfected cells were washed with 500 μL of PBS buffer (Corning, 
USA) and resuspended at the density of 8 cells/mL with a total volume of 50 mL. 100 μL of the cell suspension was 
transferred into the wells of the 96 well tissue culture plates to ensure each well contained a single cell. The plates 
were incubated at 37 °C, 5% CO2 incubator (Thermo Scientific, USA). The plates were then scanned for single cell 
colonies as soon as small aggregates of cells are visible under a 4× microscope (usually after first week, depend-
ing on the growth rate of the cell line) to ensure the cell colonies were derived from a single cell. The cells were 
incubated for an additional 2–3 weeks to expand the clonal populations for further analysis and characterization.
Harvest single cell derived clones. Single cell derived clones were washed with 100 µL of 1× PBS buffer 
(Corning, USA). 1 × 105 of the cells from each clones were transferred into the PCR plate containing 25 µL “Direct 
lysis buffer”. The “Direct lysis buffer” was made by adding 10 μL of Proteinase K (Thermo Scientific, USA) to 1 mL 
DirectPCR Lysis Reagent (Thermo Scientific, USA). The PCR plate was incubated at 55 °C for 30 mins to lyse the 
cells and followed by 95 °C for 45 mins to denature the Proteinase K.
HLA gene amplification and next generation sequencing. Multiplex long-range PCR were employed 
using AllType NGS assay (One Lambda, USA) to co-amplify 11 HLA loci including HLA-A, -B, -C, -DRB1,3,4,5 
-DQB1 -DPB1, -DQA1 and -DPA1. HLA-A, -B, -C, -DQA1, and -DPA1 were amplified from 5′UTR to 3′UTR, and 
remaining loci are beginning at intron 1 to 3′UTR. Library construction was automated on the Biomek FX (Beckman 
coulter, USA). Sequence-ready libraries were validated and quantitated on the High Sensitivity D1000 ScreenTape 
(Agilent Technologies, USA) to allow for library normalization and equimolar pooling of all study samples on the 
Biomek FX (Beckman coulter, USA). Pooled libraries were diluted and loaded at Ion Chef (Thermo Scientific, USA) for 
template amplification. Sequencing on Ion S5 XL is followed the manufacture instruction (Thermo Scientific, USA). 
When the sequencing was done, the TSVEngine v1.2.0 (One Lambda, USA) was employed to analyze the data.
Single antigen antibody testing. Neat and serum at 1:2 dilution were treated with DTT and tested for 
HLA antibodies using the IgG-SAB Assay from One Lambda (Canoga Park, CA) as previously described44. 
Antibodies were considered positive if the MFI >1000 for HLA-A, -B, -DR, -DQ and >2000 was used for HLA-C 
and -DP to correct for the enhanced amount of HLA-C and -DP antigens conjugated to the Luminex beads com-
pared to the lower cell surface expression on lymphocytes.
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Flow cytometric analysis of HLA protein expression. Expression of HLA-B locus antigens in the 
edited cell lines containing the HLA-B*38:68Q allele and control cells were determined by flow cytometry using 
a FITC-conjugated monoclonal anti-IgG Bw4 antibody (One Lambda, USA). Approximately 105 cells were incu-
bated with 0.5, 1, and 2 μL (10 mg/mL) anti-Bw4 monoclonal antibody on ice for 30 mins. Isotype control cells 
were incubated with 0.5 μL of FITC-conjugated mouse IgG secondary antibody (Jackson ImmunoResearch, 
USA). After staining, cells were washed with 1× PBS buffer (Corning, USA) containing 2% FBS (Omega, USA) 
and suspended in 300 μL of PBS/2% FBS. TEM665 homozygous HLA-B*38:01:01:01 EBV transformed B cell line 
was used as the positive control, AOH749 and K562 were used as the negative control cells. Samples were tested 
in triplicate. Analysis of HLA B locus expression was performed using FlowJo software version 10 (BD, USA).
Expression of HLA-B38 in the edited cell lines containing the HLA-B*38:68Q allele was determined using 
UCLA serum exchange sample that contains anti-B38 antibody but lacks Bw4 activity. Approximately 1.5 × 105 
cells/tube were incubated with 25 μL UCLA serum exchange serum at neat and 1:2 dilution for 30 mins at room 
temperature. After incubation, cells were washed 4 times with PBS/2% FBS followed by labeling for 20 mins at 
4 °C with an anti-human IgG FITC-conjugated antibody (Jackson ImmunoResearch, USA). Negative sera rou-
tinely used in the clinical lab were used as controls. Samples were tested in triplicate. Analysis of HLA-B38 expres-
sion was performed using FlowJo software version 10 (BD, USA).
IFN-γ induced HLA-B*38:68Q cell surface expression. The HLA-B*38:68Q homozygous cell line and 
TEM665 HLA-B*38:01:01:01 homozygous EBV transformed B cell line (served as positive control) were pre-
treated with 500 U/mL of IFN-γ (R&D Systems, USA) for 48 h. The expression of HLA-B expression of the IFN-γ 
treated and untreated cell lines were determined using monoclonal anti-IgG Bw4 antibody (One Lambda, USA) 
by flow cytometry. A FITC-conjugated anti-mIgG (BioXCell, USA) was used as an isotype control. Samples were 
tested in triplicate. Analysis of expression was performed using FlowJo software version 10 (BD, USA).
Statistical analysis. Each experiment of protein expression was tested in triplicate and the expression level 
is shown as mean fluorescence intensity (MFI) ± SD. Statistical analysis was performed the Student’s t test or 
ANOVA on GraphPad Prism 7 (GraphPad, USA). P < 0.05 was denoted as significant.
Data Availability
All data generated or analyzed during this study are included in this article.
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